Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00513786 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

A Phase 2 study of Endometrial Cancer, sponsored by David O'Malley.

Completed
Registry status
Phase 2
Development phase
38
Enrollment target
1
Study location

NCT00513786 is a Phase 2 study of Endometrial Cancer that has completed, run by David O'Malley. The registered enrollment target is 38 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00513786, a Phase 2 study of Endometrial Cancer, has completed, sponsored by David O'Malley.

COMPLETED
Registry status
Phase 2
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG bevacizumab

Study Locations (1)

Ohio

  • The Ohio State University-Division of Gyn Oncology - Columbus

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2007-08-01
Est. Completion 2017-01-03
Phase Phase 2

Sponsor

David O'Malley

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00513786

The ClinicalTrials.gov registry entry for NCT00513786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The listed sponsor is David O'Malley, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT00513786 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00513786 about?

NCT00513786 is a clinical study titled "Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma". Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.

What is the current status of trial NCT00513786?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2007-08-01. Estimated completion is 2017-01-03.

What conditions does trial NCT00513786 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT00513786?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), bevacizumab (DRUG).

Who is sponsoring clinical trial NCT00513786?

This trial is sponsored by David O'Malley, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00513786 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.